MYD88 and diffuse large B-cell lymphoma: These data are supported by previously published work showing that 11–55% of the MYD88 mutant DLBCL have a TNFAIP3 genetic alteration2,29,30 and 35–50% of WM patients harbor a TNFAIP3 loss31,32.